Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.72 USD | -1.04% | -1.33% | -11.25% |
May. 16 | Transcript : Enovis Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 04:20 PM | |
May. 02 | Enovis Q1 Shares Fall Following Q1 Results | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.25% | 2.73B | B- | ||
+13.31% | 129B | A- | ||
-9.86% | 10.92B | A- | ||
-2.59% | 8.5B | C | ||
+37.50% | 5.5B | B+ | ||
-22.36% | 4.69B | C | ||
-14.85% | 2B | - | - | |
-13.29% | 1.93B | - | ||
-28.75% | 1.65B | C- | ||
-7.38% | 1.16B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ENOV Stock
- Ratings Enovis Corporation